Diabetes
| Type 2 diabetes
Diabetes
Type 2 diabetes

Effects of tirzepatide, a dual GIP and GLP-1RA, on lipid and metabolite profiles in subjects with type 2 diabetes

book_2 Source: J Clin Endocrinol Metab. 2022;107(2):363-378.
calendar_today Published on Medfyle: May 2022
import_contacts 7 min
headphones 6 min

In this medfyle

Tirzepatide can modify metabolic factors associated with T2D risk and insulin resistance.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Expert commentary

John Wilding, DM, FRCP

University of Liverpool, Liverpool, UK

About this Medfyle
Read more arrow_downward Hide arrow_upward

This summary is based upon an article appearing in the journal entitled Journal of Endocrine Society published by Oxford University Press and was created by GlobalPort. Oxford University Press takes no responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.

The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by John Wilding, DM, FRCP.

Original article:
Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378. doi: 10.1210/clinem/dgab722. PMID: 34608929.
The authors of the original article had no part in the creation of the summary.

All Medfyle content, summaries, expert commentaries, and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of Endocrine Society/Oxford University Press.

 

This activity is supported by an educational grant from Lilly.
This activity is supported by an educational grant from Lilly.

Feedback